COMMUNIQUÉS West-GlobeNewswire

Guerbet invests in the Truffle Capital fund dedicated to medical devices and biotechnologies
14/06/2017
Villepinte, June 14, 2017 - 6:00 pm CEST - Guerbet (FR0000032526 GBT), a global specialist in contrast products and solutions for medical imaging, today announced that it has signed an equity acquisition of fifteen [...]
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlemen...
14/06/2017
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l' [...]
Informations relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du Code de commerce et l'article 223-16 du Règlement général de l'Autorité des Marchés Financ...
14/06/2017
Informations relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du Code de commerce et l'article 223-16 du Règlement général de l'Autorité des Marchés Financiers Sanofi Société [...]
Actelion announces changes to its executive team upon completion of the transaction with Johnson & Johnson
14/06/2017
ALLSCHWIL/BASEL, SWITZERLAND - 14 June 2017 - Actelion Ltd (SIX: ATLN) today announced changes to its executive team that will take effect upon the settlement of the public tender offer by Johnson & Johnson's Swiss [...]
Ordinary General Meeting of Shareholders of Probiodrug AG
14/06/2017
Ordinary General Meeting of Shareholders of Probiodrug AG All proposed resolutions approved with large majority HALLE (SAALE), Germany, 14 June 2017 - Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company [...]
Ordinary General Meeting of Shareholders of Probiodrug AG
14/06/2017
Ordinary General Meeting of Shareholders of Probiodrug AG All proposed resolutions approved with large majority HALLE (SAALE), Germany, 14 June 2017 - Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company [...]
Silmäasema Oyj: 10 largest shareholders after the end of the Initial Public Offering
14/06/2017
Stock Exchange Release 14 June 2017, at 4.30 p.m. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, HONG KONG, SOUTH AFRICA, SINGAPORE OR JAPAN OR ANY [...]
Libelium presents a white paper with 50 real IoT success stories after ten years of experience in the market
14/06/2017
The IoT company summarizes 50 of the most successful projects developed with its wireless sensor platform for smart cities, agriculture, water, logistics, parking, eHealth or environment industries. Zaragoza (Spain), 14 [...]
Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome
14/06/2017
Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome Two-stage study designed to evaluate tolerability and efficacy of [...]
RedHill Biopharma Announces Successful Phase III Top-Line Results with BEKINDA® for Acute Gastroenteritis
14/06/2017
The positive Phase III top-line results indicate that the study successfully met its primary endpoint and BEKINDA ® 24 mg was shown to be effective, safe and well tolerated in patients with acute gastroenteritis and [...]
Novo Nordisk submits application in the EU for including data from the DEVOTE trial in the Tresiba® label
14/06/2017
Bagsværd, Denmark, 14 June 2017 - Novo Nordisk today announced the submission of a Type II Variation application to the European Medicines Agency (EMA) for including data in the label for Tresiba ® (insulin degludec) [...]
Summit Therapeutics plc : 1st Quarter Results
14/06/2017
Summit Therapeutics plc ('Summit', the 'Company' or the 'Group') SUMMIT THERAPEUTICS REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED 30 APRIL 2017 AND OPERATIONAL PROGRESS Oxford, UK, 14 June 2017 - Summit [...]
Medical Prognosis Institute A/S Announces Start of Subscription Period for Rights Issue
14/06/2017
As of today, Tuesday June 14, 2017, subscription opens for a rights issue in Medical Prognosis Institute A/S (MPI). The rights issue is open to the public. Subscription period ends on Thursday June 29, 2017. A fully [...]
argenx presents update on Phase I data from ARGX-110 expansion study in patients with cutaneous T-cell lymphomas at the International Conference of Malignant Lymphoma (ICML)
14/06/2017
June 14, 2017 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the [...]
Xbrane Biopharma AB (publ) launch a long-term share savings program for employees
14/06/2017
Press release 2017-06-14 Xbrane Biopharma AB (publ) has launched a long-term share savings program for all employees in both Sweden and Italy. The purpose of the program is to create good conditions for retain and [...]
Enzymatica receives record order from STADA Arzneimittel AG
14/06/2017
Press release Lund, June 14, 2017 Enzymatica has received its largest order to date for a total of about SEK 12 million. The global pharmaceutical company STADA Arzneimittel AG ("STADA"), headquartered in Germany, has [...]
Basilea announces distribution agreement with Avir Pharma Inc. for Cresemba® (isavuconazole) and Zevtera® (ceftobiprole) in Canada
14/06/2017
Basel, Switzerland, June 14, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that Basilea Pharmaceutica International Ltd. (Basilea) has entered into a distribution and license agreement with Avir Pharma [...]
ABLYNX TO PRESENT ADDITIONAL DATA FOR ITS ANTI-IL-6R NANOBODY, VOBARILIZUMAB, AT THE ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY
14/06/2017
GHENT, Belgium, 14 June 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] announces that it will present additional data from the two Phase IIb studies in rheumatoid arthritis (RA) with its anti-IL-6R Nanobody®, [...]
Targovax ASA: Resolutions to increase the share capital in Targovax ASA in relation to exercise of employee options and settlement of restricted stock units
14/06/2017
The board of directors of Targovax ASA (the "Company") has on 14 June 2017, in accordance with the authorisations granted by the general meeting on 5 April 2017, resolved: - to increase the share capital of up to NOK [...]

Pages